Sign In
Buy BIOA
$16.04
-0.500 (-3.02%)
At Close: Jun 03, 2026
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
10:30pm, Wednesday, 21'st Jan 2026
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidat
BioAge Announces Proposed Public Offering
04:01pm, Tuesday, 20'th Jan 2026
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product cand
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
01:05pm, Monday, 12'th Jan 2026
BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
10:15am, Saturday, 13'th Dec 2025
BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area.
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
09:00am, Thursday, 04'th Dec 2025
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a c
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
04:30pm, Tuesday, 25'th Nov 2025
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
09:00am, Friday, 07'th Nov 2025
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
04:29am, Tuesday, 04'th Nov 2025
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November
Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
04:25am, Tuesday, 04'th Nov 2025
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's third quarter report for July - September 2025 on Thursday, November
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
06:15am, Wednesday, 29'th Oct 2025
BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs.
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
06:33pm, Sunday, 26'th Oct 2025
BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites.
The BioAge lawsuit alleges investors were misled on lead drug azelaprag's safety; trial halt over liver concerns caused shares to fall 77% in one day.
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
09:30am, Monday, 15'th Sep 2025
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to ac
